Hui Feng

Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia and Neuroblastoma. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer genomic databases with the genetic and imaging capacities of the zebrafish system. Current research areas in Dr. Feng’s laboratory include: 1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression. 2) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC. 3) To identify additional genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers. The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.